IRIS
MAIO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.167
EU - Europa 8.735
AS - Asia 1.425
SA - Sud America 34
OC - Oceania 32
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 1
Totale 24.415
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.128
IE - Irlanda 2.554
GB - Regno Unito 1.825
IT - Italia 1.026
FR - Francia 794
UA - Ucraina 746
RU - Federazione Russa 637
CN - Cina 615
SE - Svezia 580
SG - Singapore 352
VN - Vietnam 283
DE - Germania 227
ES - Italia 139
FI - Finlandia 111
IN - India 52
AU - Australia 29
CA - Canada 29
BR - Brasile 26
TR - Turchia 17
HK - Hong Kong 16
KR - Corea 14
NL - Olanda 14
BE - Belgio 13
SA - Arabia Saudita 12
JP - Giappone 11
GR - Grecia 10
CI - Costa d'Avorio 8
CZ - Repubblica Ceca 8
ZA - Sudafrica 8
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
AM - Armenia 6
CH - Svizzera 6
PA - Panama 6
ID - Indonesia 5
SK - Slovacchia (Repubblica Slovacca) 5
BD - Bangladesh 4
HU - Ungheria 4
LT - Lituania 4
MY - Malesia 4
PK - Pakistan 4
PL - Polonia 4
AZ - Azerbaigian 3
BG - Bulgaria 3
BO - Bolivia 3
DK - Danimarca 3
EE - Estonia 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
CL - Cile 2
EC - Ecuador 2
HR - Croazia 2
IL - Israele 2
IM - Isola di Man 2
IR - Iran 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MA - Marocco 2
PH - Filippine 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GE - Georgia 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
KZ - Kazakistan 1
MK - Macedonia 1
MS - Montserrat 1
MX - Messico 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 24.415
Salva come PNG Salva come JPEG
Città #
Fairfield 3.013
Dublin 2.551
Southend 1.630
Woodbridge 1.444
Ashburn 1.299
Wilmington 1.135
Seattle 1.108
Houston 1.098
Cambridge 1.038
Jacksonville 750
Princeton 532
Ann Arbor 400
San Mateo 358
Siena 358
Dong Ket 280
Beijing 224
Singapore 204
Dearborn 195
San Diego 194
Chandler 171
Moscow 162
New York 147
Málaga 133
Shanghai 102
Helsinki 95
London 72
Rome 61
Milan 55
San Francisco 54
Florence 48
Nanjing 42
Norwalk 40
Delhi 36
Hefei 27
Boardman 26
Toronto 25
Fremont 22
Catania 21
Salvador 20
Nanchang 19
Bologna 18
Jinan 18
Phoenix 18
Asciano 17
Palermo 17
Guangzhou 16
Kunming 15
Cascina 14
Kilburn 14
Brussels 13
Empoli 13
Redwood City 13
Riyadh 12
Hong Kong 11
Melbourne 10
Montevarchi 10
Amsterdam 9
Canberra 9
Hounslow 9
Islington 9
Prescot 9
Shenyang 9
Tokyo 9
Trieste 9
Abidjan 8
Acton 8
Lappeenranta 8
Sydney 8
Tianjin 8
Chengdu 7
Chiswick 7
Johannesburg 7
Venezia 7
Changsha 6
Marano Vicentino 6
Naples 6
Santa Clara 6
Stockholm 6
Yerevan 6
Yongsan-gu 6
Zhengzhou 6
Bratislava 5
Chicago 5
Fuzhou 5
Haikou 5
Labico 5
Lisbon 5
Los Angeles 5
Lucca 5
Mezzolombardo 5
Novara 5
Padova 5
San Giovanni Valdarno 5
Sesto Fiorentino 5
Shaoxing 5
Wandsworth 5
Altamura 4
Berlin 4
Brno 4
Brolo 4
Totale 19.697
Salva come PNG Salva come JPEG
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 210
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 209
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 178
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 175
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 170
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 170
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 169
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 151
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 148
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 138
Biomolecular strategies for therapeutic intervention in cancer 137
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 136
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors 130
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 129
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 128
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 125
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 123
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 122
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 121
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 117
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 115
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study 114
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells 113
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 113
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 111
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 111
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 108
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial 108
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 107
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls 106
Future perspectives in melanoma research. Meeting report from the “Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011” 106
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 106
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 105
Biology and clinical applications of CD40 in cancer treatment 104
THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS 102
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 101
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 100
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 99
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma 99
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010" 99
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy 99
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 98
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 98
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009 97
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells 97
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 97
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody 97
Predictors of responses to immune checkpoint blockade in advanced melanoma 97
Adjuvant pembrolizumab versus placebo in resected stage III melanoma 97
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 97
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 97
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma 97
Epigenetic drugs as immunomodulators for combination therapies in solid tumors 96
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma 96
Implementing liquid biopsies into clinical decision making for cancer immunotherapy 96
Signaling by HLA class II antigens on B cells 96
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 95
null 95
Melanoma as a model tumour for immuno-oncology 94
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 94
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy 94
Immunotherapy targeting immune check-point(s) in brain metastases 93
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 92
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability 92
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge 92
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 91
The future of mesothelioma treatment: time to shift gear 91
Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens 90
Epigenetically-regulated Tumor-Associated Antigens in melanoma 90
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response 90
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 89
Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study) 88
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 87
null 87
Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study 87
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial 87
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 87
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 86
Peptide-based vaccines for cancer therapy 86
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 86
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients 85
The role of BRAF V600 mutation in melanoma 85
Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs) 85
Introduction: Cancer epigenetics and epigenetic treatment of cancer 85
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology 85
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 85
HLA and prognostic factors in primary breast cancer 85
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) 85
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy 84
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study 84
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial 84
Anti-Tyrosinase Antibodies participate in the immune-response to vaccination with antiidiotypic antibodies mimicking the the High-Molecular-Weight-Melanoma-Associated-Antigen 83
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) 83
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) 83
Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity 82
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma 82
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 82
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF(V600)-mutated Metastatic Melanoma 82
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program 81
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 81
Totale 10.499
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.874
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.517 0 0 24 1.136 1.170 934 1.295 1.381 948 810 249 570
2020/20215.633 172 734 401 407 319 811 270 1.103 211 422 195 588
2021/20223.530 179 419 383 96 44 160 121 153 223 523 373 856
2022/20233.179 414 175 653 405 76 705 87 126 160 146 171 61
2023/20243.602 96 81 277 89 83 1.021 1.242 110 62 40 68 433
2024/2025719 337 382 0 0 0 0 0 0 0 0 0 0
Totale 25.509